Your browser doesn't support javascript.
[Clinical benefit of Tocilizumab and other immunomodulating agents for treatment of COVID-19]. / Klinischer Nutzen von Tocilizumab und anderen immunmodulatorischen Substanzen bei COVID-19.
Hornuss, Daniel; Giesen, Roland; Biever, Paul; Kern, Winfried V.
  • Hornuss D; Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg.
  • Giesen R; Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg.
  • Biever P; Klinik für Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie, Infektiologie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg.
  • Kern WV; Klinik für Kardiologie I - Universitäts-Herzzentrum Freiburg-Bad Krozingen, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg.
Dtsch Med Wochenschr ; 146(23): 1538-1542, 2021 Nov.
Article in German | MEDLINE | ID: covidwho-1537357
ABSTRACT
The pathophysiological course of COVID-19 can be distinguished in a phase of viral replication and an inflammatory phase. Hyperinflammatory processes promote the development of severe COVID-19. Therefore, immunomodulating agents came into focus. Dexamethasone has already become standard of care for treatment of severe COVID-19. Two large randomized trials and a meta-analysis of collectively nine randomized trials showed a reduced mortality in patients with severe COVID-19 if Tocilizumab - an IL-6-rezeptor antagonist - was added to standard of care. Treatment with Baricitinib - a JAK 1/2 inhibitor - may also be beneficial for patients without or on low oxygen supplementation. National and international guidelines recommend Tocilizumab for treatment of severe COVID-19. Treatment with JAK inhibitors is an option for hospitalized patients with moderate COVID-19. It should be emphasized that comedication of JAK inhibitors and Tocilizumab is not recommended. Further high quality research is required for the widespread use of immunomodulating agents in COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Immunomodulating Agents / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: German Journal: Dtsch Med Wochenschr Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Immunomodulating Agents / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: German Journal: Dtsch Med Wochenschr Year: 2021 Document Type: Article